Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 25.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity provides 4.25 Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit www.absurgery.org/
CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Astellas, Celgene Corporation, Eisai Inc., Genentech, Lilly, Novartis Pharmaceuticals Corporation, and PUMA Biotechnology.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
13th Annual School of Breast Oncology®
Click here to download brochure
Emory University Conference Center
OverviewAn increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. This intensive 3-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators. The School of Breast Oncology® not only provides a comprehensive overview for fellows or oncologists who are new to practice, but also serves as a valuable refresher course with updates on the latest data and changes to standards of care for the oncologist who has been in practice for several years or more.
This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.
At the conclusion of this activity, participants should be better prepared to:
- Explain breast cancer pathology, prognostic/predictive markers, and tumor biology in the context of stratifying risk among patients with breast cancer
- Review accepted imaging and diagnostic standards for breast cancer
- Apply biomarkers, molecular assays, and other risk assessment tools to optimize clinical decision-making for the patient with breast cancer
- Explain evidence-based recommendations concerning the use of surgical, radiation, and medical therapies to manage breast cancer
- Discuss current approaches for the management of early stage or locally advanced breast cancer
- Incorporate personalized approaches concerning the use of systemic therapies for advanced forms of breast cancer
- Describe proactive strategies to mitigate the impact and occurrence of treatment related toxicities in the setting of breast cancer
- Identify patients with breast cancer for referral to a clinical trial
|Module 1: Breast Carcinogenesis & Management of High-Risk Disease|
|Module 2: Breast Imaging|
|Module 3: Breast Surgery|
|Module 4: Breast Radiation Therapy|
|Module 5: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy|
|Module 6: Treatment of HER2-Positive Disease|
|Module 7: Systemic Treatment of Advanced/Metastatic Disease|
|Module 8: Organ-Targeted Treatment of Metastatic Disease|
|Module 9: Toxicity Management and Survivorship Considerations|
Click here to see the full agenda and session titles.
Joyce O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network
Curriculum Development CommitteeWilliam J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Feinberg School of Medicine
Frankie Ann Holmes, MD, FACP
Associate Director, Breast Oncology Research
Eleftherios Mamounas, MD, MPH, FACS
Comprehensive Breast Program
UF Health Cancer Center -- Orlando Health
Anne Moore, MD
Medical Director, Weill Cornell Breast Center
Weill Cornell Medical College
New York, NY
Lori J. Pierce, MD, FASTRO
Professor of Radiation Oncology
University of Michigan School of Medicine
Vice Provost for Academic and Faculty Affairs
University of Michigan
Ann Arbor, MI
Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Faculty, Staff, and Planners' Disclosures
The following individuals have no relevant financial relationships with commercial interests to disclose:
David Euhus, MD, FACS; Carol Fabian, MD; William J. Gradishar, MD, FASCO, FACP; Karin Hahn, MD, MSc, MPH; Syed A. Hoda, MD; Frankie Ann Holmes, MD, FACP; Anne McTiernan, MD, PhD; Anne Moore, MD; Soonmyung Paik, MD; David M. Schuster, MD; Lawrence J. Solin, MD, FACR, FASTRO; Jeffrey N. Weitzel, MD; Suzanna Zick, ND, MPH
The staff of Physicians’ Education Resource®, LLC.
The following individuals have relevant financial relationships with commercial interests to disclose:
Carey K. Anders, MD – Consultant: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Lilly, Genentech, Nektar Therapeutics, Kadmon Corporation; Research Funding: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Puma Biotechnology, Lilly, Kadmon Corporation – all uncompensated; Douglas W. Arthur, MD – Consultant: ImpediMed, Advanced Radiation Therapy; Claudine Isaacs, MD – Grant/ Research Support: Novartis; Speaker’s Bureau: Genentech, Celgene Corporation; Henry M. Kuerer, MD, PhD, FACS – Grant/ Research Support: Genomic Health; Consultant: Gerson Lehrman Group, Lightpoint Medical, Inc.; Other: McGraw-Hill Publishing; Charles Loprinzi, MD – Grant/Research Support: Bristol-Myers Squibb, Pfizer, Janssen; Consultant: Cubist Pharmaceuticals, Mitsubishi Tanabe Pharma, PledPharma; Eleftherios Mamounas, MD, MPH, FACS – Consultant: Genomic Health, Celgene Corporation, Pfizer, Novartis; Speaker’s Bureau: Genomic Health, Roche/ Genentech; Ruth O’Regan, MD – Consultant: Genentech, Pfizer, AstraZeneca; Joyce O’Shaughnessy, MD – Advisory Board/ Consultant: Arno Therapeutics, Celgene Corporation, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Johnson & Johnson, Lilly, med fusion, Merrimack Pharmaceuticals, Millennium: The Takeda Oncology Company, Novartis, Pfizer, sanofi-aventis; Lori J. Pierce, MD, FASTRO – Shareholder: PFS Genomics (founder's shares); Elizabeth Rafferty, MD – Grant/Research Support: Principal Investigator, Research Grant from Hologic, Inc. for investigation of breast tomosynthesis; Edward H. Romond, MD – Grant/ Research Support: Genentech/ Roche; Hope S. Rugo, MD – Speakers Bureau: Genomic Health; Grant/Research Support: Amgen Inc., Eisai, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Inc., Merck & Co., Inc., Novartis, OBI Pharma, Inc., Pfizer, Plexxikon Inc., Roche; Hani Sbitany, MD – Speaker’s Bureau: LifeCell; Joseph Sparano, MD – AstraZeneca, Novartis, Celgene Corporation, Genentech/Roche, Lilly, Celldex Therapeutics; Catherine Van Poznak, MD – Grant/Research Support: Bayer
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
You must be logged in to PER to register for this meeting
Or Register for PER now